605 related articles for article (PubMed ID: 16179929)
21. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
Liu RB; Rabkin SD
Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
23. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
24. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Toda M; Martuza RL; Rabkin SD
Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic herpes simplex virus vectors for cancer virotherapy.
Varghese S; Rabkin SD
Cancer Gene Ther; 2002 Dec; 9(12):967-78. PubMed ID: 12522436
[TBL] [Abstract][Full Text] [Related]
26. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
27. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
30. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
33. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.
Yu Z; Li S; Huang YY; Fong Y; Wong RJ
Cancer Gene Ther; 2007 Aug; 14(8):738-47. PubMed ID: 17525764
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
Castelo-Branco P; Passer BJ; Buhrman JS; Antoszczyk S; Marinelli M; Zaupa C; Rabkin SD; Martuza RL
Gene Ther; 2010 Jun; 17(6):805-10. PubMed ID: 20220784
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
36. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
38. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
39. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
40. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
